Home/ Stocks/ NAMS

NewAmsterdam Pharma Company N.V. Ordinary Shares

NAMS XNAS

$27.96 +0.29 (+1.05%) ▲ 15-min delayed

Open

$28.05

High

$28.23

Low

$27.51

Volume

572.0K

Market Cap

$3.31B

About NewAmsterdam Pharma Company N.V. Ordinary Shares

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 100 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$3.70M	$-64,135,000	$-0.52
Q1 2026	$3.04M	$-48,441,000	$-0.40
FY 2025	$22.50M	$-203,819,000	$-1.72
Q3 2025	$348.0K	$-72,005,000	$-0.61

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for NAMS yet. Check out our latest market news or earnings calendar.

Get NAMS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on NewAmsterdam Pharma Company N.V. Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.